Eli Lilly leans on new ADA obesity and diabetes data as investors frame it as a “winner”

Eli Lilly is heading into the latest cycle of obesity and cardiometabolic hype with fresh conference data that investors can point to across multiple pipeline stages. Ahead of the American Diabetes Association’s 86th Scientific Sessions in New Orleans (June 5-8), Lilly set out a slate designed to show both durability behind its established franchise and differentiated results from next-generation candidates. The company’s presentations also included an investor event on June 6 to review disclosures tied to the meeting.

A central focus at ADA was retatrutide, Lilly’s investigational once-weekly triple receptor agonist targeting GIP, GLP-1, and glucagon. In Lilly’s summary of its Phase 3 program, retatrutide showed “powerful weight loss” in adults with obesity in TRIUMPH-1, with results reported as up to an average of 70.3 pounds (28.3%) at 80 weeks. In TRIUMPH-1, Lilly also said the studies supported its broader aim to expand choice across patients as their needs evolve.

Lilly paired the obesity data with Phase 3 results in type 2 diabetes from TRANSCEND-T2D-1, where retatrutide was reported to lower A1C by up to an average of 2.0% and weight by up to an average of 36.6 pounds (16.8%) at 40 weeks. Those figures, presented by Lilly in the ADA preview materials, are part of the company’s argument that its pipeline is designed to compete on both glucose control and weight outcomes.

The other major ADA spotlight was Foundayo (orforglipron), Lilly’s oral GLP-1 investigational medicine. Lilly described it as “the only oral GLP-1 taken without food or water restrictions,” and said its Phase 3 ACHIEVE program included multiple head-to-head comparisons in type 2 diabetes. In ACHIEVE-2, Lilly said Foundayo lowered A1C by up to 1.7% versus 0.8% with dapagliflozin at 40 weeks. In ACHIEVE-3, Lilly said Foundayo was superior to oral semaglutide, delivering better A1C reduction and 73.6% greater relative weight loss at 52 weeks.

Lilly’s messaging at ADA also drew on the fact that its current market position is already tied tightly to GLP-1 and dual agonist demand. In a regulatory filing covering the first quarter of 2026, the company said Mounjaro and Zepbound accounted for 65% of its total revenue for the three months ended March 31, 2026. That concentration helps explain why new clinical readouts can matter beyond pure scientific interest, because they may affect how quickly doctors and payers consider switching or expanding treatment lines.

Policy and access are also part of the backdrop for the obesity drug market. In the same filing, Lilly discussed agreements with the U.S. government and described a Medicare “GLP-1 Bridge” program, under which Medicare beneficiaries would have access to discounted Lilly obesity medicines starting July 1, 2026 through December 31, 2027. Lilly said uptake from expanded access was unknown and that it continued to engage on longer-term Medicare access.

Outside Lilly’s own disclosures, a Yahoo Finance report characterized the company as the “clear winner” coming out of the ADA meeting in New Orleans, citing an analyst view after the event. The report’s specific rationale was not available in full here due to access limits on the original page, so the characterization should be treated as sentiment rather than a quantifiable trial outcome. What Lilly did lay out clearly in advance were the trial endpoints and comparative claims summarized above for retatrutide and orforglipron, both still in investigational status.

Going forward, the immediate items to watch are whether the ADA results get reinforced in full abstracts, whether Lilly provides additional sponsor communications around dosing and safety, and how quickly regulators and payers move to incorporate next-generation therapies into treatment choices. Lilly’s June 6 investor event also offers a concrete next milestone for the company’s interpretation of the meeting and what it is trying to emphasize for the market.